Key result
The PFA P2Y assay demonstrated a moderate correlation (r=-0.701) and 75% agreement with light transmittance aggregometry for monitoring clopidogrel therapy in elderly cardiovascular patients.
Why the study?
Does the PFA P2Y assay accurately assess platelet function in elderly cardiovascular patients receiving clopidogrel compared to LTA and TEG?
Cross-Sectional (n=141)
No
Does the PFA P2Y assay accurately assess platelet function in elderly cardiovascular patients receiving clopidogrel compared to LTA and TEG?
Effect estimate: r=-0.701
p-value: p=<0.001
The PFA P2Y assay is a feasible point-of-care alternative to LTA for monitoring clopidogrel response in elderly patients, though its clinical predictive value requires further validation.
No takes yet. Share an insight, caveat, or question.
Supports PFA P2Y as point-of-care option; leaves open outcome validation before guiding clopidogrel therapy.
Tian et al. (2016) conducted a cross-sectional in Cardiovascular disease receiving clopidogrel treatment (n=141). PFA P2Y assay vs. Light transmittance aggregometry (LTA) and Thromboelastograph (TEG) was evaluated on Correlation between PFA P2Y and LTA (r=-0.701, p=<0.001). The PFA P2Y assay demonstrated a moderate correlation (r=-0.701) and 75% agreement with light transmittance aggregometry for monitoring clopidogrel therapy in elderly cardiovascular patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: